Novavax Inc vs Pinterest Inc — how do they compare? Novavax Inc trades at $7.96 (market cap $1.31B), while Pinterest Inc trades at $22.91 (market cap $13.45B). The key difference: Pinterest Inc is far larger — about 10.3× Novavax Inc's market cap. Which is the better fit depends on your goals.
| NVAX | PINS | |
|---|---|---|
Market Cap | $1.31B | $13.45B |
Sector | Health | Media |
52-Week High | $11.19 | $37.95 |
52-Week Low | $6.22 | $15.42 |
Enterprise Value | $889.30M | $13.37B |
Signals from Pluang's Aura AI — not financial advice
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
Pinterest (PINS) trades at $22.93, down 5.91% over 24 hours, reflecting market disappointment despite strong Q2 2026 earnings beats. Revenue growth remains robust at 18% year-over-year, driven by AI-powered ads and record user growth to 640 million monthly active users. Technical indicators show a bullish moving average signal but neutral oscillators, with key support at $23. Recent news highlights a federal securities lawsuit investigation and CFO stock sales, adding volatility.
The outlook is mixed: solid fundamentals and a $28.69 analyst price target suggest upside, but competitive ad markets and lukewarm Q3 guidance pose risks. Investor sentiment is cautious despite bullish analyst consensus, with the stock's high P/E ratio of 69.85 requiring sustained growth to justify valuations. Key opportunities lie in international expansion and AI monetization, while legal and competitive pressures are headwinds.
Trailing returns across standard periods
Latest headlines on both assets
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →Pinterest is an online product and idea discovery platform that helps users gather ideas on everything from recipes to cook to destinations to travel to. Founded in 2010, the platform consists of a largely female audience, at roughly two thirds of its more than 365 million monthly active users. The company generates revenue by selling digital ads and is now rolling out more in-platform e-commerce features.
Read more on PINS →